Skip to main
ACOG

ACOG Stock Forecast & Price Target

ACOG Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Alpha Cognition is a pharmaceutical company focused on developing treatments for neurodegenerative diseases, including its current leading product, ZUNVEYL. Financial and commercial metrics have shown strong growth and continued market uptake, indicating a positive outlook for the company. Upcoming pipeline initiatives and post-approval studies are expected to provide substantial support for further commercial expansion. Risks include slower market uptake and setbacks in clinical testing. A new board director with extensive experience in the biopharmaceutical industry has been added to the company's leadership team. Based on a discounted cash flow valuation methodology, Alpha Cognition's prospects suggest a total enterprise value of $580M, with a 12-month price objective of $20 per share.

Bears say

Alpha Cognition is performing better than expected in terms of revenue and net loss, with an estimated full-year 2026 revenue of $26 million and a net loss of $1.28 per share. However, the negative impact of changes in the fair value of warrants and moderately higher operating expenses led to a net loss of $0.40 per share in the second quarter. Additionally, there are risks to consider, including potential issues with market uptake of their lead product, ZUNVEYL, and setbacks in clinical testing. The recent settlement agreement eliminates certain future payment obligations, but could also potentially limit the company's future revenue potential. Based on a discounted cash flow valuation, the current price target for Alpha Cognition is $18 per share, representing potential downside risk compared to the current trading price.

ACOG has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alpha Cognition Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alpha Cognition Inc (ACOG) Forecast

Analysts have given ACOG a Strong Buy based on their latest research and market trends.

According to 5 analysts, ACOG has a Strong Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alpha Cognition Inc (ACOG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.